1. Home
  2. STVN vs HALO Comparison

STVN vs HALO Comparison

Compare STVN & HALO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • STVN
  • HALO
  • Stock Information
  • Founded
  • STVN 1949
  • HALO 1998
  • Country
  • STVN Italy
  • HALO United States
  • Employees
  • STVN N/A
  • HALO N/A
  • Industry
  • STVN Containers/Packaging
  • HALO Biotechnology: Biological Products (No Diagnostic Substances)
  • Sector
  • STVN Consumer Discretionary
  • HALO Health Care
  • Exchange
  • STVN Nasdaq
  • HALO Nasdaq
  • Market Cap
  • STVN 6.6B
  • HALO 7.4B
  • IPO Year
  • STVN 2021
  • HALO N/A
  • Fundamental
  • Price
  • STVN $23.20
  • HALO $52.81
  • Analyst Decision
  • STVN Buy
  • HALO Buy
  • Analyst Count
  • STVN 6
  • HALO 9
  • Target Price
  • STVN $25.08
  • HALO $63.56
  • AVG Volume (30 Days)
  • STVN 294.9K
  • HALO 1.7M
  • Earning Date
  • STVN 08-05-2025
  • HALO 08-05-2025
  • Dividend Yield
  • STVN 0.26%
  • HALO N/A
  • EPS Growth
  • STVN N/A
  • HALO 55.40
  • EPS
  • STVN 0.50
  • HALO 3.76
  • Revenue
  • STVN $1,215,562,040.00
  • HALO $1,084,306,000.00
  • Revenue This Year
  • STVN $8.69
  • HALO $25.77
  • Revenue Next Year
  • STVN $10.67
  • HALO $18.01
  • P/E Ratio
  • STVN $48.09
  • HALO $14.04
  • Revenue Growth
  • STVN 3.81
  • HALO 25.64
  • 52 Week Low
  • STVN $16.56
  • HALO $42.01
  • 52 Week High
  • STVN $25.75
  • HALO $70.51
  • Technical
  • Relative Strength Index (RSI)
  • STVN 49.43
  • HALO 41.21
  • Support Level
  • STVN $22.70
  • HALO $53.54
  • Resistance Level
  • STVN $24.80
  • HALO $55.60
  • Average True Range (ATR)
  • STVN 1.09
  • HALO 1.24
  • MACD
  • STVN -0.03
  • HALO 0.09
  • Stochastic Oscillator
  • STVN 50.79
  • HALO 4.62

About STVN Stevanato Group S.p.A.

Stevanato Group SpA is a provider of drug containment, drug delivery and diagnostic solutions to the pharmaceutical, biotechnology and life sciences industries. It delivers an integrated, end-to-end portfolio of products, processes, and services that address customer needs across the entire drug life cycle including development, clinical, and commercial stages. It has two segments; Biopharmaceutical and Diagnostic Solutions which generates key revenue, includes all the products, processes and services developed and provided for the containment and delivery of pharmaceutical and biotechnology drugs and reagents, as well as the production of diagnostic consumables and its other segment is Engineering. Geographically, the company derives majority revenue from Europe, Middle East and Africa.

About HALO Halozyme Therapeutics Inc.

Halozyme Therapeutics Inc is a biotechnology company focused on developing and commercializing novel oncology therapies. The company seeks to create therapies focused on human enzymes that alter tumors. Halozyme focuses on developing its proprietary products in therapeutic areas with a focus on oncology, and licensing its technology to biopharmaceutical companies to collaboratively develop products. The company's operations are based in the United States, with minimal long-lived assets located internationally.

Share on Social Networks: